Evidence map›Paper›PMID 40168161›Full record

ArticleJournal of the American Society of Nephrology : JASN2025

TRPML-1 Dysfunction and Renal Tubulopathy in Mucolipidosis Type IV.

Giuseppina Grieco, Sandro Montefusco, Edoardo Nusco, Antonella Capuozzo, Francesca Cervellini, Elena Polishchuk, Martha Bishop, Antonio Miele, Luciano D'Apolito, Claudia La Vecchia and 10 more

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Giuseppina GriecoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.ORCID 0000-0001-6466-3047
Sandro MontefuscoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Edoardo NuscoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Antonella CapuozzoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Francesca CervelliniTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.ORCID 0000-0002-1926-540
Elena PolishchukTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Martha BishopDepartment of Neurology, Massachusetts General Hospital Center for Genomic Medicine, Harvard Medical School, Boston, Massachusetts.
Antonio MieleDepartment of Medical Translational Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy.ORCID 0000-0001-8959-1780
Luciano D'ApolitoDepartment of Medical Translational Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy.ORCID 0000-0003-4109-3680
Claudia La VecchiaTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Miriam AuriliaTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.ORCID 0000-0002-6641-3321
Michela SchiavoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Leopoldo StaianoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.ORCID 0000-0001-7017-1516
Marcella CesanaTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.ORCID 0000-0002-9099-8681
Rebecca ObermanMucolipidosis Type IV Foundation, Atlanta, Georgia.
Anna V LynchDepartment of Neurology, Massachusetts General Hospital Center for Genomic Medicine, Boston, Massachusetts.
Patricia MusolinoDepartment of Neurology, Massachusetts General Hospital Center for Genomic Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-8724-5649
Francesco TrepiccioneDepartment of Medical Translational Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy.ORCID 0000-0002-0622-6612
Yulia GrishchukDepartment of Neurology, Massachusetts General Hospital Center for Genomic Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-4684-4159
Diego Luis MedinaTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.ORCID 0000-0002-7347-2645

Funding

Fondazione Telethon, Million dollar bike ride grant program MDBR-23-029-ML4
6 · The paper itself

Abstract

Background: Loss-of-function mutations in the lysosomal channel transient receptor potential cation channel (TRPML-1) cause mucolipidosis type IV (MLIV), a rare lysosomal storage disease characterized by neurological defects, progressive vision loss, and achlorhydria. Recent reports have highlighted kidney disease and kidney failure in patients with MLIV during the second to third decade of life; however, the molecular mechanisms driving kidney dysfunction remain poorly understood. Methods: A cross-sectional review of medical records from 21 patients with MLIV (ages 3–43 years) was conducted to assess kidney function impairment. In addition, we examined the kidney phenotype of MLIV mice at various ages, along with human kidney cells silenced for TRPML-1 and primary tubular cells from wild-type and MLIV mice. Immunohistology and cell biology approaches were used to phenotype nephron structure, the endolysosomal compartment, and inflammation. Kidney function was assessed through proteomic analysis of mouse urine and in vivo kidney filtration measurements. Results: Of the 21 patients with MLIV, only adults were diagnosed with stage 2–3 CKD. Laboratory abnormalities included lower eGFR and higher levels BUN/creatine in blood and proteinuria. In MLIV mice, we observed significant alterations in endolysosomal morphology, function, and impaired autophagy in proximal and distal tubules. This led to the accumulation of megalin (LRP2) in the subapical region of proximal tubular cells, indicating a block in apical receptor–mediated endocytosis. In vivo and in vitro experiments confirmed reduced fluid-phase endocytosis and impaired uptake of ligands, including β-lactoglobulin, transferrin, and albumin in MLIV proximal tubular cells. Urine analysis revealed tubular proteinuria and enzymuria in mice with MLIV. In addition, early-stage disease was marked by increased inflammatory markers, fibrosis, and activation of the proinflammatory transcription factor NF-κB, coinciding with endolysosomal defects. Importantly, adeno-associated viral–mediated TRPML-1 gene delivery reversed key pathological phenotypes in MLIV mice, underscoring TRPML-1's critical role in kidney function. Conclusions: Our findings link TRPML-1 dysfunction to the development of kidney disease in MLIV.

Indexed as

KidneyMucolipidosesTransient Receptor Potential ChannelsAdolescentAdultAnimalsAutophagyCross-Sectional StudiesEndocytosisFemaleFibrosisHumansKidney Function TestsLysosomesMaleMiceMCOLN1 protein, humanProteomeTransient Receptor Potential Channels

Identifiers

PMID40168161
PMCPMC11975236

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.